Patents by Inventor Guangmei ZHANG

Guangmei ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200405793
    Abstract: Disclosed is the use of a mevalonate metabolic pathway inhibitor and an alphavirus in preparing an anti-tumor drug. The mevalonate metabolic pathway inhibitor can be used in preparing an alphavirus anti-tumor synergist. Disclosed are a pharmaceutical composition containing the mevalonate metabolic pathway inhibitor and the alphavirus, a drug kit containing the mevalonate metabolic pathway inhibitor and the alphavirus, and the use of the mevalonate metabolic pathway inhibitor and the alphavirus in treating tumors, especially those that are insensitive to the alphavirus.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 31, 2020
    Inventors: Guangmei YAN, Jiankai LIANG, Wenbo ZHU, Haipeng ZHANG, Yuan LIN, Jing CAI, Shoufang GONG
  • Patent number: 10835539
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20200085892
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 19, 2020
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei YAN, Xiao XIAO, Jun HU, Kai LI, Jiankai LIANG, Yuan LIN, Haipeng ZHANG, Suizhen LIN
  • Publication number: 20200041548
    Abstract: Non-fault disturbance-based method and system for measuring short-circuit capacity of a power grid on site including: connecting or disconnecting a reactive compensation device to or from a power grid point of common coupling, to generate a disturbance on a power grid; obtaining total active power and total reactive power of a load of the point of common coupling before the disturbance; determining a vector difference between a voltage of the power grid point of common coupling before the disturbance and a voltage of the power grid point of common coupling after the disturbance; obtaining a voltage effective value of the power grid point of common coupling before the disturbance; obtaining a capacity of the reactive compensation device; and determining a short-circuit capacity of the point of common coupling according to total active power, total reactive power, vector difference between voltages, voltage effective value, and capacity of the reactive compensation device.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 6, 2020
    Applicant: Power Grid Planning Research Institute of Guizhou Power Grid Co., Ltd.
    Inventors: Pu DENG, Zhenghang HAO, Zhenming LIU, Yi XUE, Guangmei ZHANG, Zhuo CHEN, Qingming ZHAO, Xueyong TANG, Qingsheng LI, Yu ZHANG, Sha ZHANG, Xianggang HE, Jian WANG, Sibin LU, Ke YANG
  • Patent number: 10517909
    Abstract: Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: December 31, 2019
    Assignee: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD
    Inventors: Guangmei Yan, Xiao Xiao, Jun Hu, Kai Li, Jiankai Liang, Yuan Lin, Haipeng Zhang, Suizhen Lin
  • Publication number: 20190262358
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Application
    Filed: March 25, 2019
    Publication date: August 29, 2019
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Patent number: 10357500
    Abstract: Use of 5?-androstane-3?,5,6?-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5?-androstane-3?,5,6?-triol treatment can effectively reduce vasogenic edema of brain tissue of Macaca fascicularis caused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Guangzhou Cellprotek Pharmaceutical Co., Ltd.
    Inventors: Wei Yin, Jiesi Chen, Guangmei Yan, Bingzheng Lu, Wenbo Zhu, Haiyan Hu, Pengxin Qiu, Yijun Huang, Jingxia Zhang
  • Publication number: 20190183948
    Abstract: This invention belongs to the field of biomedicine and relates to use of Bcl-xL inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that the Bcl-xL inhibitor can be used as an anti-tumor synergist for oncolytic virus. The present invention also relates to a pharmaceutical composition comprising Bcl-xL inhibitor and oncolytic virus, a pharmaceutical kit comprising Bcl-xL inhibitor and oncolytic virus, and use of Bcl-xL inhibitor and oncolytic virus for treating tumors, especially, tumors that are not sensitive to the oncolytic virus.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 20, 2019
    Applicant: GUANGZHOU VIROTECH PHARMACEUTICAL CO., LTD.
    Inventors: Guangmei YAN, Yaqian TAN, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Jing CAI, Wenbo ZHU, Wei YIN
  • Publication number: 20190167737
    Abstract: Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Jing CAI, Yuan LIN, Haipeng ZHANG, Suizhen LIN, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN
  • Publication number: 20190167641
    Abstract: The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.
    Type: Application
    Filed: August 18, 2017
    Publication date: June 6, 2019
    Applicant: Guangzhou Virotech Pharmaceutical Co., Ltd.
    Inventors: Guangmei YAN, Haipeng ZHANG, Yuan LIN, Suizhen LIN, Jing CAI, Shoufang GONG, Jun HU, Xiao XIAO, Kai LI, Jiankai LIANG, Yaqian TAN, Wenbo ZHU, Wei YIN